Comparative clinical study of a new 17D thermostable yellow fever vaccine. 1986

J C Roche, and A Jouan, and B Brisou, and R Rodhain, and B Fritzell, and C Hannoun

The immunogenicity and the safety of a new heat-stable 17D yellow fever vaccine have been assessed in a randomized comparative study by reference to a non-stabilized vaccine preparation. Seronegative adults were used and 115 and 143 were given the heat-stable and the non-stabilized vaccine, respectively. Fifty two days after the immunization, haemagglutination inhibiting antibodies were found in 77.6 and 73.9% of the vaccinees, neutralizing antibodies in 99.3 and 100% of them. The percentage of seroconversion and the geometric mean of antibody titres were not significantly different. No complaints or adverse reactions in association with the vaccines were recorded. This study demonstrates the high immunogenicity of this new stabilized vaccine whose stability has already been proven.

UI MeSH Term Description Entries
D008297 Male Males
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006358 Hot Temperature Presence of warmth or heat or a temperature notably higher than an accustomed norm. Heat,Hot Temperatures,Temperature, Hot,Temperatures, Hot
D006385 Hemagglutination Inhibition Tests Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination. Hemagglutination Inhibition Test,Inhibition Test, Hemagglutination,Inhibition Tests, Hemagglutination,Test, Hemagglutination Inhibition,Tests, Hemagglutination Inhibition
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D014765 Viral Vaccines Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease. Viral Vaccine,Vaccine, Viral,Vaccines, Viral

Related Publications

J C Roche, and A Jouan, and B Brisou, and R Rodhain, and B Fritzell, and C Hannoun
January 1988, Journal of biological standardization,
J C Roche, and A Jouan, and B Brisou, and R Rodhain, and B Fritzell, and C Hannoun
December 2013, The American journal of tropical medicine and hygiene,
J C Roche, and A Jouan, and B Brisou, and R Rodhain, and B Fritzell, and C Hannoun
October 1981, Journal of biological standardization,
J C Roche, and A Jouan, and B Brisou, and R Rodhain, and B Fritzell, and C Hannoun
January 2009, Vaccine,
J C Roche, and A Jouan, and B Brisou, and R Rodhain, and B Fritzell, and C Hannoun
January 2000, Microbes and infection,
J C Roche, and A Jouan, and B Brisou, and R Rodhain, and B Fritzell, and C Hannoun
September 1958, Tropical and geographical medicine,
J C Roche, and A Jouan, and B Brisou, and R Rodhain, and B Fritzell, and C Hannoun
April 2009, Zhongguo yi miao he mian yi,
J C Roche, and A Jouan, and B Brisou, and R Rodhain, and B Fritzell, and C Hannoun
May 2011, Biologicals : journal of the International Association of Biological Standardization,
J C Roche, and A Jouan, and B Brisou, and R Rodhain, and B Fritzell, and C Hannoun
October 2015, Vaccine,
J C Roche, and A Jouan, and B Brisou, and R Rodhain, and B Fritzell, and C Hannoun
February 2006, Virology,
Copied contents to your clipboard!